Literature DB >> 16051400

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

Hans O Hallander1, Lennart Gustafsson, Margaretha Ljungman, Jann Storsaeter.   

Abstract

Longitudinal serum samples were collected from 542 children that had participated in a Swedish pertussis vaccine trial 1992-1995 [Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334(6):349-355] and who did not contract pertussis. The sera were analyzed for post vaccination antibody decay and for booster response of anti-PT (IgG antibodies against pertussis toxin), as measured by ELISA. Generally, an initial rapid decay of antitoxin antibody concentration was followed by a slower decay; the change occurring when the geometric mean level of antitoxin concentration reached 8-9 ELISA Units/mL (EU/mL). The time needed to reach this level was 8-9 months after the third dose in a 2, 4, and 6 months schedule. A "best-fit" combined regression model was used to predict when 50% of the children have less than the minimum level of detection of anti-PT (1EU/mL). This occurred about 65 months after dose 3 at an age of 6 years. The anti-PT response to a booster dose was evident but the post-booster geometric mean values decreased with number of years after the third dose and the response appeared later. The results indicate that a pre-school booster might be considered at 6 years of age or earlier.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051400     DOI: 10.1016/j.vaccine.2005.06.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.

Authors:  Rose-Minke Schure; Lotte H Hendrikx; Lia G H de Rond; Kemal Oztürk; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

Review 2.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

3.  Identification of pertussis-specific effector memory T cells in preschool children.

Authors:  Lia de Rond; Rose-Minke Schure; Kemal Öztürk; Guy Berbers; Elisabeth Sanders; Inonge van Twillert; Maria Carollo; Françoise Mascart; Clara M Ausiello; Cecile A C M van Els; Kaat Smits; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

4.  Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia.

Authors:  Patricia Campbell; Peter McIntyre; Helen Quinn; Linda Hueston; Gwendolyn L Gilbert; Jodie McVernon
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

5.  Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.

Authors:  Sabine C de Greeff; Hester E de Melker; Pieter G M van Gageldonk; Joop F P Schellekens; Fiona R M van der Klis; Liesbeth Mollema; Frits R Mooi; Guy A M Berbers
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 6.  Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.

Authors:  Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling
Journal:  Cochrane Database Syst Rev       Date:  2021-09-06

7.  Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?

Authors:  Audrey J King; Tamara van Gorkom; Han G J van der Heide; Abdolreza Advani; Saskia van der Lee
Journal:  BMC Genomics       Date:  2010-01-26       Impact factor: 3.969

8.  Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.

Authors:  Hans O Hallander; Mikael Andersson; Lennart Gustafsson; Margaretha Ljungman; Eva Netterlid
Journal:  APMIS       Date:  2009-12       Impact factor: 3.205

9.  Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates.

Authors:  Susana Scott; Marianne van der Sande; Tisbeh Faye-Joof; Maimuna Mendy; Bakary Sanneh; Fatou Barry Jallow; Hester de Melker; Fiona van der Klis; Pieter van Gageldonk; Frits Mooi; Beate Kampmann
Journal:  Pediatr Infect Dis J       Date:  2015-04       Impact factor: 2.129

10.  Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.

Authors:  Nihal M Ibrahim; Ebtsam M El-Kady; Somiaa A Eissa; Ahmed F Wahby
Journal:  J Adv Res       Date:  2015-03-21       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.